Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

CVD Still the Leading Cause of Death and Disease Globally

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

Acute HF Patients Live Longer When Seen by Specialists

News Daily News

Acute HF Patients Live Longer When Seen by Specialists

Michael O'Riordan

August 09, 2024

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

New Risk Score Better for Capturing Medical Urgency for Heart Transplantation

News Daily News

New Risk Score Better for Capturing Medical Urgency for Heart Transplantation

Michael O'Riordan

February 19, 2024

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

News Daily News

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

Michael O'Riordan

September 18, 2023

PCI Doesn’t Cut Arrhythmias in Severe LV Dysfunction: REVIVED-BCIS2 Analysis

News Daily News

PCI Doesn’t Cut Arrhythmias in Severe LV Dysfunction: REVIVED-BCIS2 Analysis

August 14, 2023

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

News Daily News

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Michael O'Riordan

June 23, 2023

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.